🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Brisbane
Clinical trial register · Australia

Clinical Trials in Brisbane, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Melbourne 32 Westmead 30 Brisbane 28 Clayton 22 Frankston 21
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC28 Eli Lilly and Company22 Bristol-Myers Squibb15 Sanofi10 University of Sydney7 Clear sponsor filter
Site location
Melbourne32 Westmead30 Brisbane28 Clayton22 Frankston21
All 78 locations
Target enrolment
to

Trials with a site in Brisbane

28 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene
Merck Sharp & Dohme LLC
Phase 3
876
St Leonards, Brisbane, Nedlands
2026-05-04
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
DrugsMvasi·Avastin·Sacituzumab tirumotecan·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
900
Westmead, Brisbane, East Melbourne
2026-02-16
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
675
Campbelltown, Frenchs Forest, Brisbane, South Brisbane, Frankston
2025-10-08
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272Malignant Neoplasm
DrugPatritumab deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
50
Sydney, Brisbane, Parkville
2025-05-26
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,123
Blacktown, Brisbane, Melbourne, Nedlands
2025-05-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Avastin
Merck Sharp & Dohme LLC
Phase 3
770
Sydney, Brisbane, East Melbourne, Frankston
2025-04-09
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Randwick, Brisbane, Melbourne
2024-08-16
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,530
Macquarie University, Westmead, Brisbane, Frankston
2024-06-24
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
DrugsSacituzumab tirumotecan·Leucovorin·Fluorouracil·Adrucil
Merck Sharp & Dohme LLC
Phase 1/2
220
Westmead, Brisbane, East Melbourne, Frankston, Nedlands
2024-06-20
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Concord, Brisbane, Adelaide, Clayton, Melbourne
2024-06-05
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
272
Macquarie University, Westmead, Brisbane, Murdoch
2024-04-10
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Westmead, Brisbane, Murdoch
2024-04-03
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Dubbo, Macquarie University, Westmead, Brisbane, Melbourne
2023-12-31
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Macquarie University, Westmead, Brisbane, Clayton, Melbourne
2023-12-18
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsAbraxane·Adriamycin·Taxol·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
710
St Leonards, Sydney, Brisbane, East Melbourne, Frankston
2023-12-06
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,109
Kingswood, Sydney, Brisbane, Adelaide, Clayton, Melbourne
2023-10-25
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
14,550
Bruce, Blacktown, Camperdown, Kanwal, Brisbane, Clayton, Hoppers Crossing
2023-10-09
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Westmead, Wollstonecraft, Brisbane, Melbourne, Nedlands
2023-07-19
Active, closed
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms
DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
390
Brisbane, Heidelberg
2023-06-23
Active, closed
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
NCT05766501HIV Infection
DrugDOR/ISL
Merck Sharp & Dohme LLC
Phase 3
641
Darlinghurst, Sydney, Brisbane, Melbourne
2023-03-17
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
Camperdown, Westmead, Auchenflower, Brisbane, South Brisbane
2023-03-16
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
NCT05631093HIV-1 Infection
DrugsDOR/ISL·B/F/TAF
Merck Sharp & Dohme LLC
Phase 3
553
Darlinghurst, Sydney, Brisbane, Melbourne
2023-02-20
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
NCT05630755HIV-1 Infection
DrugsDOR/ISL·B/F/TAF
Merck Sharp & Dohme LLC
Phase 3
514
Darlinghurst, Sydney, Brisbane, Melbourne
2023-02-17
Recruiting
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
NCT05562830Urothelial Carcinoma
DrugsMK-3120·Zilovertamab vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
48
Brisbane
2022-11-16
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Blacktown, Macquarie University, North Tamworth, Brisbane, Elizabeth Vale, Heidelberg, Murdoch
2022-03-15
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
280
St Leonards, Westmead, Brisbane, Clayton, Melbourne, Subiaco
2022-02-03
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsDocetaxel·Paclitaxel·Bevacizumab·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
643
Westmead, Brisbane, Melbourne, Subiaco
2021-12-13
Active, closed
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT04938817Small Cell Lung Carcinoma
DrugsMK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab·R-DXd
Merck Sharp & Dohme LLC
Phase 1/2
110
Westmead, Brisbane, Clayton, Perth
2021-08-19
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-australia/city/brisbane

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Brisbane that also match the filters currently applied.

How many clinical trials are recruiting in Brisbane?

14 of the 28 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Brisbane), 28 studies
PhaseStudiesRecruitingShare
Phase 3201071.4%
Phase 1/26421.4%
Phase 2207.1%

Most active sponsors

Lead sponsors with the most studies (Brisbane)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC2814
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.